Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 823 across all filing types
Latest filing 2026-06-05 Declaration of Voting R…
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a brief announcement disclosing the total number of shares and voting rights as of a specific date, citing French commercial code and AMF regulations. It does not present financial results or a meeting’s voting outcome but specifically announces voting rights data. This matches the "Declaration of Voting Results & Voting Rights Announcements" category.
2026-06-05 French
2025 Universal Registration Document
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-06-04 English
Assemblée Générale Mixte du 24 juin 2026 Modalités de mise à disposition des documents préparatoires à l’Assemblée
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a notice convening the Assemblée Générale Mixte on June 24, 2026, outlining the agenda, publication of the notice, and modalities for shareholders to access preparatory materials per Code de commerce. It serves as informational/proxy solicitation material for the upcoming shareholder meeting, rather than presenting financial results or substantive report content. Hence, it fits the Proxy Solicitation & Information Statement category.
2026-06-03 French
Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting
AGM Information Classification · 85% confidence The document is a press release announcing details of the company's upcoming Annual General Meeting (date, time, location, notice publication, procedures to obtain preparatory documents) and does not include financial data or voting results. This fits the definition of “AGM Information” (materials and presentations related to the AGM).
2026-06-03 English
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
Earnings Release Classification · 90% confidence The document is a press release summarizing the company’s full year 2025 audited consolidated financial results, including detailed financial tables, key metrics (revenues, EPS, cash flows), discussion of subsequent events and cash runway, and it announces the filing of the Universal Registration Document. It is the initial public announcement of annual financial results rather than the full annual report itself (URD). Therefore, it fits the definition of an Earnings Release. FY 2025
2026-06-03 English
OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025
Earnings Release Classification · 89% confidence The document is a press release announcing OSE Immunotherapeutics’ audited consolidated financial results for fiscal year 2025 with key highlights, summary tables, cash runway commentary, and reference to the filing of the Universal Registration Document. It is not the full annual report itself nor a certification letter, but rather an initial announcement of the yearly results, fitting the definition of an Earnings Release. FY 2025
2026-06-03 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.